Biosimilars Market Research Reports & Industry Analysis
The worldwide prescription generic drug market has stood the test of time and has endured numerous growing pains. However, it has evolved into a formidable and important participant in the complex world of health care. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market.
Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for the promotion of biosimilars is favorable in the next five years.
Biosimilars Industry Research & Market Reports
-
Europe Biosimilars Market Outlook, 2030
... first biosimilar approval in 2006. Since then, the European market has demonstrated robust growth in biosimilar uptake, driven by an aging population, increasing healthcare costs, and the need for affordable treatment options for chronic and ... Read More
-
Global Biosimilars Market Overview, 2025-30
... biologics expire, biosimilars present an opportunity to reduce healthcare costs and improve patient access to life-saving therapies. The demand for biosimilars is driven by the growing prevalence of chronic diseases such as cancer, diabetes, and ... Read More
-
Australia Biosimilars Market Overview, 2030
... medicines, medical devices, blood and blood products, including biosimilars. TGA has approved 65 biosimilars within the product classes of human growth hormone, granulocyte colony-stimulating factor, insulin, erythropoietin, follicle stimulating hormone (FSH), monoclonal antibody and tumour ... Read More
-
Mexico Biosimilars Market Overview, 2030
... to biosimilars because they were worried about their safety, effectiveness, and interchangeability. With more clinical information coming to hand and real-world experience of biosimilar performance, healthcare professionals are increasingly confident to prescribe biosimilars. Alongside this, ... Read More
-
Middle East & Africa Biosimilars Market Outlook, 2030
... biosimilars as cost-effective alternatives. Governments across the region are actively seeking to reduce healthcare spending while expanding patient access to life-saving treatments. This has resulted in a gradual yet steady increase in the adoption of ... Read More
-
South Africa Biosimilars Market Overview, 2030
... technologically advanced and effective medicines such as biologicals (originator) and biosimilars (equivalent of the biological). From a competition perspective, biosimilars have gained interest due to their positive impact on price competition resulting in more affordable ... Read More
-
China Biosimilars Market Overview, 2030
... corresponding regulations and guidelines to encourage the development of biosimilars. China, as a populous nation with a substantial demand for biologic therapies, has made substantial investments in the research and development (R&D) of a number ... Read More
-
Japan Biosimilars Market Overview, 2030
... product while being less expensive. They are an alternative to costly biologic therapeutics, providing patients with greater access to treatments while potentially saving healthcare systems money. Despite a sluggish start, Japan’s biosimilar market looks set ... Read More
-
United Kingdom Biosimilars Market Overview, 2030
... an active substance of an already approved biological medicinal product, known as the reference product. Offering the same clinical effectiveness and safety as their reference products, biosimilars are interchangeable with the original biological medicine and ... Read More
-
Germany Biosimilars Market Overview, 2030
... Medicines Agency (EMA), which establishes standards for their research and approval, oversees the approval of biosimilars in Germany. With additional criteria to prove comparability with the reference biologic, the approval procedure for biosimilars in Germany ... Read More
-
Canada Biosimilars Market Overview, 2030
... opportunity for cost savings for Canadian payers. Unlike small molecule medicines, which experience a relatively quick market adjustment after generic entry, most originator biologics in Canada continue to dominate the market after the introduction of ... Read More
-
Asia-Pacific Biosimilars Market Outlook, 2030
... regulatory frameworks, and expanding patient base. While Asia-Pacific is the quickest-growing market for biosimilars due to low production costs, skilled and cheap labor availability, slender regulations laid down by governments, there are, however, high for ... Read More
-
North America Biosimilars Market Outlook, 2030
... and diabetes. The United States and Canada are the primary contributors to this market in North America, with the U.S. being the dominant force due to its massive healthcare expenditure, sophisticated pharmaceutical infrastructure, and a ... Read More
-
Global Biosimilars Market Outlook, 2030
... approved reference biologic, with no clinically meaningful differences in terms of safety, purity, and potency. Unlike generic drugs for small molecules, which are chemically synthesized and relatively straightforward to replicate, biosimilars are derived from living ... Read More
-
Columbia Biosimilars Market Overview, 2030
... advances. INVIMA has implemented measures to streamline biosimilar evaluations while maintaining high technical standards. This environment is favorable for market entry, but it also demands strong technical preparation. In Colombia, the regulatory body for the ... Read More
-
Argentina Biosimilars Market Overview, 2030
... out with its distinctive structure and policies that have shaped its biopharmaceutical sector. Over the course of this century, the biopharmaceutical industry in Argentina has emerged as a critical player in the country's healthcare sector. ... Read More
-
UAE Biosimilars Market Overview, 2030
... system with first-rate facilities and cutting-edge medical technology. The government offers free or inexpensive healthcare services to its inhabitants and residents, and the private sector meets the requirements of those who can afford to pay ... Read More
-
France Biosimilars Market Overview, 2030
... etc.), that biologics and their biosimilars mainly target chronic conditions such as cancer, chronic inflammatory diseases, or autoimmune diseases. The France Biosimilars market will grow with the increased incidence of chronic illnesses, rising healthcare expenses, ... Read More
-
Spain Biosimilars Market Overview, 2030
... pharmaceutical industry in Spain, offering a more affordable and accessible alternative to biological drugs. Currently, there are a number of biosimilars available in Spain, including versions of drugs used to treat cancer, autoimmune diseases, and ... Read More
-
South America Biosimilars Market Outlook, 2030
... involvement in the global biosimilars market is evolving, with several local pharmaceutical companies collaborating with multinational corporations to manufacture and commercialize biosimilars regionally. Brazil, the largest pharmaceutical market in Latin America, has established a robust ... Read More
-
Saudi Arabia Biosimilars Market Overview, 2030
... To date, there is a lack of published data about physicians’ knowledge and awareness about the required information about biosimilars. Biosimilars are biological products designed to closely resemble and exhibit no clinically significant differences from ... Read More
-
South Korea Biosimilars Market Overview, 2030
... an extensive pipeline portfolio which includes antibody biosimilars for the treatment of rheumatoid arthritis and colorectal cancer as well as drugs to treat hepatitis B, influenza, rabies, breast cancer, and seasonal influenza, and Samsung Bioepis ... Read More
-
Italy Biosimilars Market Overview, 2030
... by implementing policies that encourage the adoption of biosimilars, thereby promoting competition and reducing healthcare expenditures. The national procurement framework, established under Law 232/2016, allows physicians to choose among the top three lowest-priced biosimilars in ... Read More
-
Russia Biosimilars Market Overview, 2030
... bolster the biosimilars sector. The ""Pharma 2030 Strategy"" aims to localize the production of vital medicines, including biosimilars, to reduce dependence on foreign imports and enhance national security. This initiative focuses on increasing domestic manufacturing ... Read More
-
United States Biosimilars Market Overview, 2030
... because they are typically priced at least 25% lower, providing a means to administer cutting-edge biologic therapy while also managing cost of care. In fact, the US health care system has saved an estimated $23.6 ... Read More
Research Assistance
